Key Highlights
- Shareholders received a cash payment of $39.00 per share and contingent value rights tied to a CVR Trust.
- All outstanding preferred shares bearing 8.625% and 8.375% coupon rates were redeemed at a par value of $0.05 per share.
- The record date for the special meeting listed 17,678,742 common shares, and Nasdaq trading was halted prior to the merger.
XOMA Royalty Corp (NASDAQ: XOMA) announced the consummation of its merger with Ligand Pharmaceuticals on July 14, 2026. The transaction restructured XOMA as a wholly owned subsidiary of Ligand and triggered a series of corporate actions, including cash distribution, CVR issuance, and a Nasdaq delisting.
Merger Completion
The merger became effective on July 14, 2026, converting each existing common share, with a par value of $0.0075 per share, into a cash entitlement and a contingent value right (CVR). The cash component was set at $39.00 per share, payable without interest and subject to tax withholding.
Cash and CVR Distribution
Investors received the $39.00 cash payment together with CVRs that provide for future payouts based on the performance of the CVR Trust. The CVR mechanism follows the terms set out in the merger agreement, offering an additional layer of contingent consideration for shareholders.
Preferred Stock Redemption
Prior to the effective time of the merger, the company redeemed all outstanding preferred shares that carried an 8.625% dividend rate (Series A) and those that carried an 8.375% dividend rate (Series B). Both series were issued with a par value of $0.05 per share, and redemption included payment of accrued dividends through the redemption date.
Holding Company Reorganization
A holding‑company reorganization preceded the merger, converting each pre‑reorganization share into a share of the new holding entity. Equity awards were also swapped to reflect the new share structure, ensuring continuity for holders of stock‑based compensation.
Board and Officer Changes
Following the merger, three directors from the merging subsidiary assumed board seats for XOMA, while seven incumbent directors resigned. Officer roles transferred to the incoming directors, aligning leadership with the parent company’s governance framework.
Delisting and Reporting Suspension
XOMA notified Nasdaq of the merger completion and requested an immediate halt to trading, effecting a delisting before market open on July 14, 2026. The company also intends to file the requisite termination notices to suspend its reporting obligations under the Exchange Act.
Additional Documentation
The loan agreement previously filed by the company. The press release announcing the merger.
Sector Context
The consolidation reflects a broader trend in the biotechnology and pharmaceutical sectors, where companies seek to combine complementary pipelines and streamline capital structures. By merging with Ligand Pharmaceuticals, XOMA positions itself to benefit from Ligand’s extensive development platform while providing shareholders with immediate cash value and ongoing participation through the CVR mechanism.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_17_2026_18_51_41_746812.jpg)


Please wait processing your request...